Biopharmaceutical global outsourcing solutions provider PCI Pharma Services has expanded its global clinical footprint with the creation of a new Clinical Center of Excellence (Coe ) at its Berlin location in Germany.
The company’s major investment in the COE will represent a new flagship site for customers.
This latest investment comes as part of the company’s overall global network expansion strategy.
PCI noted that the COE completion is expected in January next year.
PCI Pharma Services Global Clinical Operations and Supply vice-president and general manager Brian Keesee said: “With this expansion, our Berlin Clinical Center of Excellence will address the needs of European and global clients.
“Berlin is an excellent logistical hub that will serve as a proactive solution to Brexit, ensuring there are no gaps in the supply chain and our clients conducting clinical trials in all parts of Europe continue to be served.”
The new Berlin COE is a 17,000ft² space used for primary and secondary packaging. It will also be used as storage of pharmaceutical and biopharmaceutical therapies at different temperatures.
It is strategically located to serve the EU-based clinical trials ecosystem, which currently has over 38,100 clinical trials sites that are active.
Of the 27-member countries of the EU, France and Germany stand first and second, with 7,370 and 4,418 active trial sites, respectively.
PCI Pharma Services CEO Salim Haffar said: “Our strategy has always been to increase the capacity and capabilities of our clinical trial services network, and with the acquisition of Bellwyck Pharma Services earlier this year, we are taking the next step to enhance our capabilities at our new Berlin facility to support the growing clinical trial market in Europe and beyond.
“This investment will provide clients with global clinical trial solutions for their life-changing medicines, ensuring continuity of patient supply to match growing market demands.”
In February, PCI Pharma Services acquired Canadian company Bellwyck Pharma Services to bring its clinical trial services to Canada and continental Europe.